Kamada Ltd. EBITDA 2011-2026 | KMDA

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Kamada Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
26.2 M	20.1 M	10.1 M	4.53 M	-696 K	19.2 M	22.8 M	19.3 M	7.44 M	-1.98 M	-8.2 M	-8.71 M	6.7 M	4.61 M	541 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
26.2 M	-8.71 M	8.12 M

Quarterly EBITDA Kamada Ltd.

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
26.2 M	7.82 M	7.07 M	7.8 M	20.1 M	5.29 M	5.64 M	4.04 K	10.1 M	4.37 K	2.63 M	289 K	-	-	-	-	-	-804 K	-	-	-	7.76 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
26.2 M	-804 K	7.13 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	-15.3 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	-6.4 M	-	1.35 %	$ 17.8 M	China
Amphastar Pharmaceuticals AMPH	172 M	$ 16.89	-2.37 %	$ 789 M	USA
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Compugen Ltd. CGEN	-34.6 M	$ 2.85	-5.94 %	$ 266 M	Israel
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Coherus BioSciences CHRS	-180 M	$ 1.58	-3.37 %	$ 185 M	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
AstraZeneca PLC AZN	19.5 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Arcturus Therapeutics Holdings ARCT	-73.2 M	$ 7.46	-4.73 %	$ 204 M	Israel
Athira Pharma ATHA	-101 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	-11.9 M	-	0.74 %	$ 768 M	Israel
Galera Therapeutics GRTX	-2.54 M	-	-32.59 %	$ 7.61 M	USA
Eton Pharmaceuticals ETON	3.2 M	$ 29.73	-0.77 %	$ 800 M	USA
Exelixis EXEL	901 M	$ 50.09	-1.98 %	$ 13.6 B	USA
Midatech Pharma plc MTP	-8.64 M	-	-18.52 %	$ 27.3 M	Britain
Fortress Biotech FBIO	-69.8 M	$ 2.47	7.39 %	$ 68.9 M	USA
Forte Biosciences FBRX	-70.6 M	$ 22.53	-5.97 %	$ 292 M	USA
Fennec Pharmaceuticals FENC	-6.28 M	$ 9.51	2.92 %	$ 272 M	USA
AbCellera Biologics ABCL	-199 M	$ 4.03	-8.52 %	$ 1.2 B	Canada
Autolus Therapeutics plc AUTL	-262 M	$ 1.57	-1.26 %	$ 418 M	Britain
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
BioNTech SE BNTX	-1.4 B	$ 88.94	-3.32 %	$ 21.5 B	Germany
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Galectin Therapeutics GALT	-20.1 M	$ 2.22	-5.74 %	$ 142 M	USA
Gilead Sciences GILD	10.4 B	$ 129.56	-1.9 %	$ 161 B	USA
Genmab A/S GMAB	6.57 B	$ 26.79	-0.41 %	$ 1.73 B	Danmark
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 3.36	-5.62 %	$ 5.53 M	Israel
Aeterna Zentaris AEZS	-10.7 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Grifols, S.A. GRFS	1.19 B	$ 7.67	-1.6 %	$ 5.21 B	Spain
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Enlivex Therapeutics Ltd. ENLV	-18.7 M	$ 0.72	-1.76 %	$ 32.9 M	Israel
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Esperion Therapeutics ESPR	60.4 M	$ 3.13	0.32 %	$ 651 M	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 21.66	0.42 %	$ 2.76 B	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA